Written question asked by Lord Hunt of Kings Heath (Labour) on Monday, 28 October 2019, in the House of Lords. It was due for an answer on Monday, 11 November 2019. It was answered by Baroness Blackwood of North Oxford (Conservative) on Monday, 4 November 2019 on behalf of the Department of Health and Social Care.
Liothyronine
- Question
-
To ask Her Majesty's Government what action they propose to take in relation to thyroid patients who, having previously had successful treatment on dosages of 20mcg and above of liothyronine, are now facing a restriction on the dosage.
- Answer
-
Whilst NHS England and NHS Improvement will regularly review its guidance, at present, there are no plans to revisit the specific recommendations for liothyronine unless new clinical evidence comes to light. Decisions on appropriate treatment for thyroid patients and doses are taken in accordance with a clinical management plan and implemented by the clinician.
Secondary information
- Type
- Written question
- Reference
- HL456
- Session
- 2019-19
- Subjects
- Prescriptions Liothyronine
- Link
- View this Written question on www.parliament.uk
Librarians' tools
- Timestamp
- 2019-12-11 16:32:51 +0000
- URI
- http://data.parliament.uk/writtenparliamentaryquestion/lords/2019-19/HL456
- In Indexing
- http://indexing.parliament.uk/Content/Edit/1?uri=http://data.parliament.uk/writtenparliamentaryquestion/lords/2019-19/HL456
- In Solr
- https://search.parliament.uk/claw/solr/?id=http://data.parliament.uk/writtenparliamentaryquestion/lords/2019-19/HL456